| Common Name | ACD22-VCMMAE, DCDT2980S, FCU2803, RG-7593, RO5541072-000 |
|---|---|
| Synonyms | CD22, SIGLEC2, BL-CAM, SIGLEC-2, Siglec2, SIGLEC2FLJ22814 |
| Applications | ELISA |
| Recommended Dilutions | ELISA 1:5000-10000 |
| Buffer | Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions. |
| Formulation & Reconstitution | Powder |
| Host Species | Humanized |
| IgG type | IgG1 |
| Reactivity | Human |
| Storage | |
| Storage & Shipping | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized proteins are shipped at ambient temperature. |
| Guarantee | 12 months from date of dispatch |
| Background | Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. |
Anti-CD22 (pinatuzumab biosimilar) mAb
Price: 50μg $80.00 ; 100 μg $160.00
Product Data
Images
Figure 1. ELISA plate pre-coated by 2 μg/ml (100 μl/well) Human CD22, hFc-His tagged protein (PME100005) can bind Anti-CD22 Neutralizing antibody in a linear range of 3.2-400 ng/ml.
Figure 2. HEK293 cell line transfected with irrelevant protein (B) and human CD22 (A) were surface stained with Anti-CD22 mAb 1 μg/ml (pinatuzumab) followed by Alexa 488-conjugated anti-human IgG secondary antibody.